open access

Vol 75, No 4 (2017)
Original articles
Published online: 2016-12-27
Submitted: 2016-08-05
Accepted: 2016-11-14
Get Citation

Galectin-3 is associated with coronary plaque burden and obstructive sleep apnoea syndrome severity

Hamdi Pusuroglu, Umut Somuncu, Ismail Bolat, Ozgur Akgul, Vesile Ornek, Hayriye Ak Yıldırım, Emre Akkaya, Huseyin Karakurt, Aydın Yıldırım, Ayfer Utku Savaş
DOI: 10.5603/KP.a2016.0185
·
Kardiol Pol 2017;75(4):351-359.

open access

Vol 75, No 4 (2017)
Original articles
Published online: 2016-12-27
Submitted: 2016-08-05
Accepted: 2016-11-14

Abstract

Background: Obstructive sleep apnoea syndrome (OSAS) is reported to be associated with hypertension, coronary artery disease, atrial fibrillation, and heart failure. Galectin-3 plays an important role in the regulation of inflammation, development of cardiac fibrosis, and remodelling. A significant relationship between galectin-3 and the total number of coronary plaques and the macrocalcified plaque structures of patients with type 2 diabetes mellitus has been reported.

Aim: The aim of this study was to investigate the association between galectin-3 level and coronary plaque burden as well as OSAS severity in patients with OSAS.

Methods: A total of 87 consecutive patients with a diagnosis of OSAS and 21 age- and gender-matched control subjects were recruited for the present study. The patients with OSAS were also categorised according to their apnoea hypopnoea index (AHI) as follows: mild (AHI = 5–15), moderate (AHI = 15–30), and severe (AHI > 30). All study subjects underwent coronary computed tomography angiography to detect coronary atherosclerosis. Also, all participants of serum galectin-3 concentrations were measured.

Results: Mean galectin-3 level was significantly higher in patients with OSAS compared to control subjects (p < 0.001) and in the severe OSAS group, compared to the moderate and mild OSAS groups (p < 0.001). Correlation analysis indicated significant positive relationships between galectin-3 concentrations and the total number of coronary plaques (p < 0.001), high-sensitivity C-reactive protein (p = 0.001), and severity of OSAS (p < 0.001). In multivariate analysis, galectin-3 (p = 0.01) and age (p = 0.025) were significant independent predictors of coronary atherosclerosis, after adjusting for other risk factors. Also, it has been found that galectin-3 concentration is a predictor of OSAS severity (p = 0.001).

Conclusions: Galectin-3 is associated with coronary atherosclerosis and OSAS severity in OSAS patients.

Abstract

Background: Obstructive sleep apnoea syndrome (OSAS) is reported to be associated with hypertension, coronary artery disease, atrial fibrillation, and heart failure. Galectin-3 plays an important role in the regulation of inflammation, development of cardiac fibrosis, and remodelling. A significant relationship between galectin-3 and the total number of coronary plaques and the macrocalcified plaque structures of patients with type 2 diabetes mellitus has been reported.

Aim: The aim of this study was to investigate the association between galectin-3 level and coronary plaque burden as well as OSAS severity in patients with OSAS.

Methods: A total of 87 consecutive patients with a diagnosis of OSAS and 21 age- and gender-matched control subjects were recruited for the present study. The patients with OSAS were also categorised according to their apnoea hypopnoea index (AHI) as follows: mild (AHI = 5–15), moderate (AHI = 15–30), and severe (AHI > 30). All study subjects underwent coronary computed tomography angiography to detect coronary atherosclerosis. Also, all participants of serum galectin-3 concentrations were measured.

Results: Mean galectin-3 level was significantly higher in patients with OSAS compared to control subjects (p < 0.001) and in the severe OSAS group, compared to the moderate and mild OSAS groups (p < 0.001). Correlation analysis indicated significant positive relationships between galectin-3 concentrations and the total number of coronary plaques (p < 0.001), high-sensitivity C-reactive protein (p = 0.001), and severity of OSAS (p < 0.001). In multivariate analysis, galectin-3 (p = 0.01) and age (p = 0.025) were significant independent predictors of coronary atherosclerosis, after adjusting for other risk factors. Also, it has been found that galectin-3 concentration is a predictor of OSAS severity (p = 0.001).

Conclusions: Galectin-3 is associated with coronary atherosclerosis and OSAS severity in OSAS patients.

Get Citation

Keywords

galectin-3, obstructive sleep apnoea syndrome, coronary atherosclerosis

About this article
Title

Galectin-3 is associated with coronary plaque burden and obstructive sleep apnoea syndrome severity

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 75, No 4 (2017)

Pages

351-359

Published online

2016-12-27

DOI

10.5603/KP.a2016.0185

Bibliographic record

Kardiol Pol 2017;75(4):351-359.

Keywords

galectin-3
obstructive sleep apnoea syndrome
coronary atherosclerosis

Authors

Hamdi Pusuroglu
Umut Somuncu
Ismail Bolat
Ozgur Akgul
Vesile Ornek
Hayriye Ak Yıldırım
Emre Akkaya
Huseyin Karakurt
Aydın Yıldırım
Ayfer Utku Savaş

References (23)
  1. Somers VK, Dyken ME, Clary MP, et al. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest. 1995; 96(4): 1897–1904.
  2. Mooe T, Franklin KA, Holmström K, et al. Sleep-disordered breathing and coronary artery disease: long-term prognosis. Am J Respir Crit Care Med. 2001; 164(10 Pt 1): 1910–1913.
  3. Ip MSM, Tse HF, Lam B, et al. Endothelial function in obstructive sleep apnea and response to treatment. Am J Respir Crit Care Med. 2004; 169(3): 348–353.
  4. Shahar E, Whitney CW, Redline S, et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med. 2001; 163(1): 19–25.
  5. Lattimore JDL, Celermajer DS, Wilcox I. Obstructive sleep apnea and cardiovascular disease. J Am Coll Cardiol. 2003; 41(9): 1429–1437.
  6. Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004; 110(19): 3121–3128.
  7. Gruson D, Ko G. Galectins testing: new promises for the diagnosis and risk stratification of chronic diseases? Clin Biochem. 2012; 45(10-11): 719–726.
  8. Yu X, Sun Y, Zhao Y, et al. Prognostic value of plasma galectin-3 levels in patients with coronary heart disease and chronic heart failure. Int Heart J. 2015; 56(3): 314–318.
  9. de Boer RA, van Veldhuisen DJ, Gansevoort RT, et al. The fibrosis marker galectin-3 and outcome in the general population. J Intern Med. 2012; 272(1): 55–64.
  10. Ozturk D, Celik O, Satilmis S, et al. Association between serum galectin-3 levels and coronary atherosclerosis and plaque burden/structure in patients with type 2 diabetes mellitus. Coron Artery Dis. 2015; 26(5): 396–401.
  11. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep. 1999; 22(5): 667–689.
  12. OʼBrien E, Asmar R, Beilin L, et al. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. Journal of Hypertension. 2005; 23(4): 697–701.
  13. Genuth S, Alberti KG, Bennett P, et al. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003; 26(11): 3160–3167.
  14. Austen WG, Edwards JE, Frye RL, et al. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation. 1975; 51(4 Suppl): 5–40.
  15. Wolk R, Kara T, Somers VK. Sleep-disordered breathing and cardiovascular disease. Circulation. 2003; 108(1): 9–12.
  16. Kwon Y, Duprez DA, Jacobs DR, et al. Obstructive sleep apnea and progression of coronary artery calcium: the multi-ethnic study of atherosclerosis study. J Am Heart Assoc. 2014; 3(5): e001241.
  17. Gunnarsson SI, Peppard PE, Korcarz CE, et al. Obstructive sleep apnea is associated with future subclinical carotid artery disease: thirteen-year follow-up from the Wisconsin sleep cohort. Arterioscler Thromb Vasc Biol. 2014; 34(10): 2338–2342.
  18. Kent BD, Garvey JF, Ryan S, et al. Severity of obstructive sleep apnoea predicts coronary artery plaque burden: a coronary computed tomographic angiography study. Eur Respir J. 2013; 42(5): 1263–1270.
  19. Arik B, Inci MF, Gumus C, et al. Advanced age and apnea-hypopnea index predict subclinical atherosclerosis in patients with obstructive sleep apnea syndrome. Multidiscip Respir Med. 2013; 8(1): 9.
  20. Kepez A, Niksarlıoğlu EY, Hazırolan T, et al. Evaluation of association between obstructive sleep apnea and coronary risk scores predicted by tomographic coronary calcium scoring in asymptomatic patients. Anadolu Kardiyol Derg. 2011; 11(5): 428–435.
  21. Liu YH, D'Ambrosio M, Liao Td, et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol. 2009; 296(2): H404–H412.
  22. van Kimmenade RR, Januzzi JL, Ellinor PT, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006; 48(6): 1217–1224.
  23. Tang WH, Shrestha K, Shao Z, et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol. 2011; 108(3): 385–390.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl